UCB (OTCMKTS:UCBJY) Shares Gap Up – Still a Buy?

Shares of UCB SA (OTCMKTS:UCBJY) gapped up prior to trading on Friday . The stock had previously closed at $145.76, but opened at $151.28. UCB shares last traded at $151.67, with a volume of 5,833 shares.

Analyst Ratings Changes

Several equities research analysts have commented on UCBJY shares. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Zacks Research downgraded UCB from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

UCB Price Performance

The company’s 50-day moving average price is $145.09 and its two-hundred day moving average price is $146.40. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.